Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 42.8%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 67,700 shares, a decrease of 42.8% from the January 31st total of 118,400 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 127,400 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Trading of SAB Biotherapeutics

Several large investors have recently made changes to their positions in SABS. Northern Trust Corp acquired a new stake in SAB Biotherapeutics during the 4th quarter worth $43,000. Geode Capital Management LLC boosted its position in SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after acquiring an additional 12,692 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new stake in SAB Biotherapeutics during the 3rd quarter valued at about $52,000. Diadema Partners LP acquired a new stake in SAB Biotherapeutics in the 4th quarter valued at about $114,000. Finally, HB Wealth Management LLC lifted its stake in SAB Biotherapeutics by 118.6% in the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after purchasing an additional 128,800 shares in the last quarter. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $12.40.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock traded down $0.03 during mid-day trading on Tuesday, reaching $1.53. 7,457 shares of the stock traded hands, compared to its average volume of 148,850. The business has a 50-day moving average of $2.87 and a 200 day moving average of $3.00. SAB Biotherapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $6.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.